Background
==========

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder affecting 1 in 3000 individuals worldwide \[[@B1]\]. The NF1 gene, located on chromosome 17q11.2, was identified by positional cloning, and its protein product, neurofibromin, functions as a tumor suppressor \[[@B2],[@B3]\]. Neurofibromin contains a central domain homologous to the Ras-GTPase-activating protein family (Ras-GAPs), which function as negative regulators of Ras proteins \[[@B4]\].

The main clinical features of NF1 are *café au lait*macules, skinfold freckling and iris Lisch nodules. Patients are at an increased risk of both benign and malignant tumors, and NF1 is thus classified as a tumor predisposition syndrome. The most common tumors are benign peripheral nerve sheath tumors (neurofibromas), which vary greatly in both number and size, and may be dermal or plexiform \[[@B5]\]. In contrast to dermal neurofibromas, which are typically small and grow as discrete lesions in the dermis, plexiform neurofibromas can develop internally along the plexus of major peripheral nerves and become quite large \[[@B6]\]. Both dermal and plexiform neurofibromas are heterogeneous tumors mainly composed of Schwann cells (60--80%), together with neurons, fibroblasts, mast cells and other cells.

About 5% of patients with NF1, neurofibromas (mainly plexiform neurofibromas) progress to malignant peripheral nerve sheath tumors (MPNSTs). More than 80% of MPNSTs are high-grade malignant tumors, corresponding to WHO grade III-IV \[[@B7]\]. MPNSTs are resistant to conventional therapies, and their deep-seated position and locally invasive growth hinder complete surgical resection. The 5-year survival rate among patients with MPNSTs ranges from 30--50%. Schwann cells are considered to be the progenitors of both neurofibromas and MPNSTs, but recent data suggest that other cell types may contribute to the development of these tumors \[[@B8]\].

The molecular mechanisms responsible for malignant progression of neurofibromas are largely unknown. Only a few relevant genetic alterations have so far been identified \[[@B9],[@B10]\]. In keeping with its role as a classical tumor suppressor gene, *NF1*loss of heterozygosity (LOH) has been found in NF1-associated MPNSTs (but also in benign neurofibromas) \[[@B11]\]. *TP53*mutations have been identified in MPNSTs but not in benign neurofibromas, indicating that the p53-mediated pathway is involved in tumor progression \[[@B12]-[@B14]\]. Consistent with the role of p53 in the progression of MPNSTs, mice that harbor both *NF1*and *TP53*mutations develop MPNSTs \[[@B15]\]. Alterations of other genes (*p16/CDKN2A*, *p14/ARF*, *p27/KIP1*, *EGFR*) are frequent in MPNSTs but not in neurofibromas \[[@B16]-[@B20]\]. Taken together, these studies suggest that loss of NF1 initiates tumor formation, and that malignant progression requires additional genetic lesions.

The recent development of efficient tools for large-scale analysis of gene expression has provided new insights into the involvement of gene networks and regulatory pathways in various tumoral processes \[[@B21]\]. These methods include cDNA microarrays, which can be used to analyze the expression of thousands of genes at a time, and real-time RT-PCR assays for more accurate and quantitative expression analysis of smaller numbers of candidate genes \[[@B22]\].

To obtain further insight into the molecular pathogenesis of MPNSTs, we used real-time quantitative RT-PCR to quantify the mRNA expression of a large number of selected genes in pooled MPNST samples, in comparison with pooled plexiform neurofibroma samples. We assessed the expression level of 489 genes involved in various cellular and molecular phenomena associated with tumorigenesis. We focused particularly on the expression of genes related to MPNSTs, and genes expressed during Schwann cell differentiation. Forty genes of interest were further investigated in nine individual MPNSTs (all arising from plexiform neurofibromas), in comparison with 14 plexiform neurofibromas.

Results
=======

We first quantified the mRNA expression level of the 489 genes (see list in annex; [Additional file 1](#S1){ref-type="supplementary-material"}) in an MPNST pool, a plexiform neurofibroma pool and a dermal neurofibroma pool. We then selected for further study those genes whose expression in the MPNST pool differed markedly (\> 10-fold) from that in both the plexiform neurofibroma pool and the dermal neurofibroma pool. These robust selection criteria (a cutoff of 10-fold expression difference in the MPNST pool) ensure identification of gene with marked interest. The mRNA expression of the genes thus identified was then determined in 9 individual MPNSTs (Table [1](#T1){ref-type="table"}) in comparison with 14 plexiform neurofibromas.

###### 

Clinical and histological characteristics of the 9 patients with MPNST

  **Patient N°/Sex/Age**   **Pain**   **Enlargement of mass**   **Neurological signs**   **Tumor localization**   **Tumor size (cm)**   **Histoprognostic grade**
  ------------------------ ---------- ------------------------- ------------------------ ------------------------ --------------------- ---------------------------
  1/F/19                   \+         \+                        \-                       Lower limb               27                    III
  2/F/18                   \+         \-                        \-                       Upper limb               20                    III
  3/M/18                   \-         \+                        \-                       Head                     15                    III
  4/M/35                   \+         \+                        \+                       Abdomen                  20                    III
  5/M/34                   \+         \+                        \+                       Lumbar                   6.5                   III
  6/M/53                   \+         \+                        \+                       Upper limb               13                    III
  7/F/24                   \+         \+                        \+                       Lumbar                   7                     I
  8/M/24                   \+         \+                        \+                       Abdomen                  20                    III
  9/M/31                   \-         \+                        \-                       Face                     15                    III

F indicates female; M, male Plus sign indicates present; minus sign, absent

mRNA expression of 489 genes in the MPNST pool relative to the plexiform and dermal neurofibroma pools
------------------------------------------------------------------------------------------------------

The MPNST, plexiform neurofibroma and dermal neurofibroma pools were each prepared by mixing identical amounts of tumor RNA from four patients. The mean *TBP*gene Ct (threshold cycle) values for the four tumor samples were 26.18 ± 0.39 (MPNST pool), 26.23 ± 1.45 (plexiform neurofibroma pool) and 26.30 ± 0.47 (dermal neurofibroma pool).

Very low levels of target gene mRNA, that were only detectable but not reliably quantifiable by means of real-time quantitative RT-PCR assays, mainly based on fluorescence SYBR Green methodology (Ct \>32), were observed for 50 (10.2%) of the 489 genes in the MPNST, plexiform and dermal neurofibroma pools.

Forty (9.1%) of the 439 remaining genes were expressed at a different level (\> 10-fold) in the MPNST pool compared to both the dermal neurofibroma and plexiform neurofibroma pools; 27 (6.1%) genes were upregulated and 13 (3.0%) were down-regulated. The *NF1*gene expression level did not differ between the dermal neurofibroma, plexiform neurofibroma and MPNST pools: the N*NF1*values (see Patients and Methods) were 1.00, 1.39 and 1.45, respectively. This lack of difference was probably due to the fact that the *NF1*gene is ubiquitously expressed and therefore expressed in the different cell components of the neurofibromas and MPNSTs, and that NF1^-/-^Schwann cells represent only a fraction of the total Schwann cell population in tumor samples.

mRNA expression of the 27 upregulated genes in 9 MPNSTs and 14 plexiform neurofibromas
--------------------------------------------------------------------------------------

The expression level of the 27 upregulated genes identified by pooled sample analysis was then determined individually in 9 MPNSTs and 14 plexiform neurofibromas. Sixteen (59.3%) of the 27 genes were significantly upregulated in the 9 MPNSTs (P \< 0.05; Table [2](#T2){ref-type="table"}).

###### 

List of the significantly up-regulated genes in the MPNSTs relative to the plexiform neurofibromas.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **GENES**          **Gene definition**                         **Gene caracterisation**   **Plexiform neurofibromas**\   **MPNSTs**\              **P**^1^   **ROC-AUC**^2^
                                                                                            **(n = 14)**                   **(n = 9)**                         
  ------------------ ------------------------------------------- -------------------------- ------------------------------ ------------------------ ---------- ----------------
  *MKI67*            Proliferation-related Ki-67 Antigen         Cell proliferation         **1.85**\[0.14--5.85\]^3^      **33.2**\[19.1--93.6\]   \<0.01     1.000

  *BIRC5/Survivin*   Survivin                                    Apoptosis                  **2.01**\[0.13--10.6\]         **26.2**\[9.39--715\]    \<0.01     0.984

  *SPP1*             Secreted phosphoprotein 1 (osteopontin)     Growth factor              **0.07**\[0.00--6.78\]         **16.2**\[6.11--58.5\]   \<0.01     0.984

  *MMP13*            Matrix metalloproteinase 13                 Extracellular matrix\      **0.18**\[0.00--15.6\]         **119**\[2.93--844\]     \<0.01     0.968
                                                                 remodeling                                                                                    

  *TERT*             Telomere reverse transcriptase              Senescence                 **0.00**\[0.00--45.4\]         **53.7**\[11.0--395\]    \<0.01     0.960

  *MMP9*             Matrix Metalloproteinase 9 (gelatinase B)   Extracellular matrix\      **0.56**\[0.00--11.4\]         **38.0**\[7.02--640\]    \<0.01     0.960
                                                                 remodeling                                                                                    

  *TERC/hTR*         Telomerase RNA component                    Senescence                 **0.76**\[0.22--4.32\]         **6.02**\[2.60--29.4\]   \<0.01     0.960

  *TOP2A*            Topoisomerase II alpha                      Cell proliferation         **2.21**\[0.27--24.5\]         **28.8**\[10.1--294\]    \<0.01     0.960

  *FOXM1*            Forkhead box M1                             Transcription factor       **1.26**\[0.30--11.1\]         **21.4**\[4.59--119\]    \<0.01     0.960

  *FOXA2/HNF3B*      Forkhead box A2 (hepatocyte\                Transcription factor       **0.00**\[0.00--2.13\]         **1.77**\[0.09--49.2\]   \<0.01     0.952
                     nuclear factor 3, beta)                                                                                                                   

  *HMMR/RHAMM*       Hyaluronan receptor                         Signaling transduction     **1.22**\[0.06--6.40\]         **16.9**\[6.31--54.8\]   \<0.01     0.922

  *CXCL5*            Chemokine (C-X-C motif) ligand 5            Growth factor              **1.79**\[0.00--52.1\]         **17.0**\[5.18--2096\]   \<0.01     0.913

  *OSF-2*            Osteoblast specific factor 2\               Growth factor              **3.25**\[0.06--42.9\]         **30.5**\[1.68--112\]    \<0.01     0.873
                     (fasciclin I-like, periostin)                                                                                                             

  *CCNE2*            Cyclin E2                                   Cell proliferation         **2.29**\[0.50--9.41\]         **11.3**\[1.68--21.9\]   \<0.01     0.873

  *EPHA7*            Ephrin Receptor EPHA7                       Growth factor receptor     **2.35**\[0.19--13.4\]         **11.3**\[1.39--93.9\]   \<0.01     0.865

  *TP73*             Tumor protein p73                           Apoptosis                  **0.89**\[0.00--12.8\]         **15.9**\[0.73--73.5\]   \<0.01     0.833
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Mann and Whitney\'s U Test ^2^ROC (*Receiver Operating Characteristics*) -- AUC (*Area Under Curve*) analysis ^3^Median \[range\] of gene mRNA levels

The 16 upregulated genes were mainly involved in cell proliferation (*MKI67*, *TOP2A*, *CCNE2*), senescence (*TERT*, *TERC/hTR*), apoptosis (*BIRC5/Survivin*, *TP73*) and extracellular matrix remodeling (*MMP13*, *MMP9*).

The capacity of each of these 16 genes to discriminate between MPNSTs and plexiform neurofibromas was then tested by ROC curve analysis. The overall diagnostic value of the 16 molecular markers was assessed in terms of the AUCs (Table [2](#T2){ref-type="table"}). Figure [1](#F1){ref-type="fig"} shows the mRNA levels of the three most discriminatory genes, namely *MKI67*(AUC-ROC, 1.000), *BIRC5/Survivin*(AUC-ROC, 0.984), and *SPP1/Osteopontin*(AUC-ROC, 0.984), in each MPNST and plexiform neurofibroma sample. For information, Figure [1](#F1){ref-type="fig"} also shows the mRNA levels of these three genes in 10 dermal neurofibromas.

![mRNA levels of *MKI67*, *BIRC5/Survivin*and *SPP1*in 10 individual dermal neurofibromas (white bars), 14 plexiform neurofibromas (gray bars) and 9 MPNSTs (black bars). Median values (and ranges) are indicated for each tumor subgroup.](1476-4598-3-20-1){#F1}

mRNA expression of the 13 down-regulated genes in 9 MPNSTs and 14 plexiform neurofibromas
-----------------------------------------------------------------------------------------

Twelve (92.3%) of the 13 genes were significantly down-regulated in the 9 MPNSTs (P \< 0.05; Table [3](#T3){ref-type="table"}).

###### 

List of the significantly down-regulated genes in the MPNSTs relative to the plexiform neurofibromas

  **GENES**   **Gene definition**                   **Gene caracterisation**          **Plexiform neurofibromas (n = 14)**   **MPNSTs (n = 9)**       **P**^1^   **ROC-AUC**^2^
  ----------- ------------------------------------- --------------------------------- -------------------------------------- ------------------------ ---------- ----------------
  *ITGB4*     Integrin beta 4                       Adhesion molecule                 **0.74**\[0.19--3.46\]^3^              **0.01**\[0.00--0.03\]   \<0.01     1.000
  *CMA1*      Chymase 1                             Mast cell-specific marker         **0.42**\[0.04--4.62\]                 **0.01**\[0.00--0.03\]   \<0.01     1.000
  *L1CAM*     L1 cell adhesion molecule             Schwann cell-specific marker      **0.32**\[0.04--1.26\]                 **0.00**\[0.00--0.03\]   \<0.01     1.000
  *MPZ*       Myelin protein zero                   Schwann cell-specific marker      **0.43**\[0.08--3.43\]                 **0.01**\[0.00--0.02\]   \<0.01     1.000
  *DHH*       Desert hedgehog homolog               Hedgehog signalling pathway       **0.84**\[0.12--10.8\]                 **0.05**\[0.01--0.15\]   \<0.01     0.992
  *S100B*     S100 calcium binding protein, beta    Schwann cell-specific marker      **0.77**\[0.14--3.03\]                 **0.01**\[0.00--0.17\]   \<0.01     0.992
  *ERBB3*     ErbB3                                 Growth factor receptor            **0.49**\[0.06--2.31\]                 **0.01**\[0.00--0.21\]   \<0.01     0.984
  *PTCH2*     Patched homolog 2                     Hedgehog signalling pathway       **0.95**\[0.07--4.66\]                 **0.05**\[0.01--0.24\]   \<0.01     0.980
  *RASSF2*    Ras association domain family 2       Signal transduction               **1.11**\[0.23--11.1\]                 **0.04**\[0.01--0.35\]   \<0.01     0.976
  *TPSB*      Tryptase beta 1 and 2                 Mast cell-specific marker         **0.96**\[0.03--2.57\]                 **0.04**\[0.01--0.07\]   \<0.01     0.952
  *SOX10*     SRY (sex determinig region Y)-box10   Schwann cell-specific marker      **0.26**\[0.00--1.18\]                 **0.01**\[0.00--0.05\]   \<0.01     0.929
  *TIMP4*     Tissue inhibitor 4 of MMP             Extracellular matrix remodeling   **0.69**\[0.02--11.5\]                 **0.03**\[0.01--0.27\]   \<0.01     0.917

^1^Mann and Whitney\'s U Test ^2^ROC (*Receiver Operating Characteristics*) -- AUC (*Area Under Curve*) analysis ^3^Median \[range\] of gene mRNA levels

The 12 down-regulated genes mainly were cell type-specific, and included Schwann cell-specific genes (*L1CAM*, *MPZ*, *S100B*, *SOX10*) and mast cell-specific genes (*CMA1*, *TPSB*). The others down-regulated genes were involved in extracellular matrix remodeling (*ITGB4*, *TIMP4*) and in the Hedgehog-Gli signaling pathway (*DHH*, *PTCH2*).

The capacity of each of these 12 genes to discriminate between MPNSTs and plexiform neurofibromas was then tested by ROC curve analysis. The overall diagnostic value of the 12 molecular markers was assessed in terms of the AUCs (Table [3](#T3){ref-type="table"}). Figure [2](#F2){ref-type="fig"} shows the mRNA levels of the three most discriminatory genes, namely *ITGB4*(AUC-ROC, 1.000), *CMA1/Chymase 1*(AUC-ROC, 1.000), and *L1CAM*(AUC-ROC, 1.000), in each MPNST and plexiform neurofibroma sample, and also in each dermal neurofibroma sample.

![mRNA levels of *ITGB4*, *CMA1/Chymase 1*and *L1CAM*in 10 individual dermal neurofibromas (white bars), 14 plexiform neurofibromas (gray bars) and 9 MPNSTs (black bars). Median values (and ranges) are indicated for each tumor subgroup.](1476-4598-3-20-2){#F2}

The mRNA levels indicated in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} (calculated as described in *Materials and Methods*) are expressed relative to the endogenous control *TBP*mRNA level, to control for the starting amount and quality of total RNA. Similar results were obtained with a second endogenous control, *RPLP0*(also known as *36B4*). Indeed, the 16 upregulated genes and the 12 down-regulated genes were also significantly up-regulated or down-regulated in the MPNSTs relative to the plexiform neurofibromas.

Discussion
==========

We used real-time quantitative RT-PCR to quantify the mRNA expression of 489 selected genes in pooled MPNST samples, in comparison with pooled plexiform neurofibroma and pooled dermal neurofibroma samples. Forty genes of interest were then investigated in 9 individual MPNSTs and 14 plexiform neurofibromas. Comparison of pool values with the mean of the corresponding individual values showed that RNA pooling was an appropriate initial screening approach, significantly limiting the required number of PCR experiments. Using the same approach, we have also shown the involvement of several molecular pathways in the genesis of plexiform neurofibroma \[[@B23]\], and other human diseases \[[@B24]\].

Real-time quantitative RT-PCR is a promising alternative to cDNA microarrays for molecular tumor profiling, being far more precise, reproducible and quantitative. Real-time RT-PCR is more useful for analyzing weakly expressed genes (such as *TERT*, *CXCL5*, *FOXM1*and *FOXA2/HNF3B*in the present study). Finally, real-time RT-PCR requires smaller amounts of total RNA (about 2 ng per target gene), and is therefore suitable for analyzing small tumors (as in the present study) or microdissected samples.

We included a number of genes known to be involved in various cellular and molecular mechanisms associated with tumorigenesis, and known to be altered (mainly at the transcriptional level) in various cancers. These genes encode proteins involved in cell cycle control, cell-cell interactions, signal transduction pathways, apoptosis, angiogenesis, etc. (about 10--20 genes were selected per pathway). After scrutinizing the literature, we also included most genes reported to be involved in neurofibromas and MPNSTs, and also genes expressed during Schwann cell differentiation.

Among the 489 genes analyzed, 28 (5.7%) showed a significantly different level of expression in MPNSTs relative to plexiform neurofibromas, suggesting that several signaling pathways are specifically involved in MPNST (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Some of our results support those reported in the literature on NF1-associated MPNSTs. First, several genes associated with cell cycle control (*MKI67*, *TOP2A*, *CCNE2*) were over-expressed in MPNSTs, suggesting higher cell proliferation rates than in plexiform neurofibromas, as previously reported by Kindblom et al. \[[@B25]\]. *MKI67*encodes Ki-67, a large protein of unknown function used as a classical histopathological marker of cell proliferation. Other proliferation-associated genes (*CCND1*, *CCNE1*, etc) were also upregulated in MPNSTs, but less markedly than *MKI67*, *TOP2A and CCNE2*. Second, most of mast cell-specific genes (*CMA1/Chymase 1*and *TPSB/Tryptase beta*) and Schwann cell-specific genes (*L1CAM*, *MPZ*, *S100B*, *SOX10*) tested here were markedly under-expressed in MPNSTs, probably owing either to a lower abundance of a particular cell type (likely mast cells) in MPNSTs relative to plexiform neurofibromas, or to dedifferentiation of a particular cell type (likely Schwann cells). Schwann cell dedifferentiation could also explain the observed under-expression of *ITGB4*and *ERBB3*, key genes in the Schwann cell lineage \[[@B26],[@B27]\]. DeClue et al. \[[@B19]\] suggested that, following acquisition of *ERBB1/EGFR*overexpression, Schwann cells may begin to dedifferentiate and lose markers such as *ERBB3*. In agreement with these data, we observed slight over-expression of *ERBB1/EGFR*in MPNSTs, whereas the two other *ERBB*family members (*ERBB2*and *ERBB4*) were normally expressed (Figure [3A](#F3){ref-type="fig"}). It is noteworthy that, in Schwann cells, *ERBB3*could be regulated by *SOX10*(found here to be under-expressed in MPNSTs), as in peripheral glial cells \[[@B28]\].

![Expression level of various genes in the dermal neurofibroma pool (white bars), the plexiform neurofibroma pool (gray bars) and the MPNST pool (black bars). A, *ERBB*family member genes; B, matrix metalloproteinase genes; C, inhibitor of metalloproteinase genes; D, chemokine genes; E, Ras signaling pathway genes; F, Hedgehog-Gli signaling pathway genes; G, Gli-regulated genes.](1476-4598-3-20-3){#F3}

Some of our results for MPNSTs are new, but are in keeping with general concepts of tumorigenesis, in which altered genes are involved in senescence, apoptosis and extracellular matrix remodeling. First, *TERT*and *TERC/hTR*, the two main components of human telomerase, were upregulated in MPNSTs. The expression patterns of *TERT*and *TERC/hTR*were very similar (r = +0.793, P = 0.00001; Spearman rank correlation test). *TERT*(human telomerase revere transcriptase) is the rate-limiting factor for telomerase activity, whereas *TERC/hTR*(human telomerase RNA) also seems to correlate to a certain extent with telomerase reactivation \[[@B24]\]. *TERT*and *TERC/hTR*are upregulated in almost all malignancies but not in benign tumors \[[@B29]\].

We also found that two genes involved in apoptosis -- *BIRC5/Survivin*and *TP73*-- were upregulated in MPNSTs. *BIRC5/Survivin*encodes an antiapoptotic protein overexpressed in common human cancers \[[@B30]\]. It is noteworthy that coexpression of *BIRC5/Survivin*and *TERT*transcripts is associated with a high risk of tumor-related death among patients with soft-tissue sarcomas \[[@B31]\]. *TP73*, the second apoptosis-related candidate gene identified here, encodes two different proteins that are expressed under the control of two independent promoters and have opposite activities, namely the transcriptionally active full-length protein TAp73, and the amino-terminally truncated dominant-negative protein Δ Np73 \[[@B32]\]. Unlike *TP53*, *TP73*is mainly regulated at the transcriptional level. TAp73 induces cell-cycle arrest and apoptosis, whereas ΔNp73 inhibits both TAp73-induced and p53-induced apoptosis. Furthermore, ΔNp73 is induced by TAp73 and p53, in a dominant-negative feedback loop that regulates p53 and p73 function \[[@B32]\]. Interesting, we found that *TAp73*transcription was significantly upregulated in MPNSTs (P \< 0.01; AUC-ROC, 0.952), while Δ*Np73*transcription was significantly down-regulated (P \< 0.01; AUC-ROC, 0.917) (data not shown).

MPNSTs showed upregulation of two matrix metalloproteinase genes (*MMP9*and *MMP13*) and down-regulation of a tissue inhibitor of metalloproteinases (*TIMP4*). MMPs are associated with extracellular matrix turnover, a process that plays a very active role in tumor invasion and metastasis \[[@B33]\]. For their part, TIMPs play a key role in extracellular matrix homeostasis by regulating MMP activity \[[@B34]\]. Many reports suggest that an MMP-TIMP imbalance may contribute to the malignant phenotype \[[@B33],[@B34]\]. The other extracellular matrix-related genes tested in the present studies showed no statistically differentially expression levels between MPNSTs and plexiform neurofibromas (Figures [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). We have previously identified *MMP9*as a major upregulated gene in plexiform neurofibromas compared to dermal neurofibromas \[[@B23]\] (Figure [3B](#F3){ref-type="fig"}), suggesting that *MMP9*upregulation may be an early event in MPNST tumorigenesis.

Finally, our results suggest that inappropriate activation of molecular signaling pathways occurs specifically in NF1-associated MPNST or in limited human tumors, particularly brain and skin tumors. MPNSTs showed upregulation of *CXCL5*, the gene encoding the chemokine ENA-78 (epithelial cell-derived neutrophil-activating peptide) \[[@B35]\]. Chemokines play fundamental roles in the development, homeostasis and functioning of the immune system, but also have effects on endothelial cells and cells of the nervous system \[[@B36]\]. *CXCL5*is physically linked, in chromosomal region 4q12-q13, to other chemokine genes with markedly similar nucleotide sequences, including *CXCL6*, *IL8 and GRO1/CXCL1*\[[@B37]\]. We found that *CXCL6*was slightly upregulated (trend toward statistical significance) in MPNSTs. We have previously detected *IL8*and *GRO1/CXCL1*upregulation in the early stages of plexiform neurofibroma tumorigenesis \[[@B23]\] (Figure [3D](#F3){ref-type="fig"}). Our results thus point to a role of paracrine and autocrine signaling defects involving these chemokines, located in 4q12-q13, in the tumorigenesis of plexiform neurofibromas and/or MPNSTs. Comparative genomic hybridization analysis has shown gains of chromosome arm 4q12-ter in both sporadic and NF1-associated MPNSTs \[[@B38]\], suggesting co-overexpression of these chemokines by a DNA amplification mechanism.

We identified two genes (*RASSF2*, *HMMR/RHAMM*) putatively involved in the Ras signaling pathway; *RASSF2*was down-regulated, whereas *HMMR/RHAMM*was upregulated. *RASSF2 is*a member of the *RASSF*family genes that encode for proteins which bind directly to Ras protein in a GTP-dependent manner via a Ras effector domain. This family currently has six members, *RASSF1*, *RASSF2*, *RASSF3*, *RIN2*, *AD037*and *NORE1*. RASSF proteins promote both cell cycle arrest and apoptosis; they behave as tumor suppressor genes, and their down-regulation might play a key role in tumorigenesis. *RASSF*genes are a new class of tumor suppressor genes for which epigenetic silencing is an overwhelming mechanism of inactivation, and somatic mutations are rare \[[@B39],[@B40]\]. Vos et al. \[[@B41]\]recently obtained evidence that *RASSF2*is specific to K-Ras, as only a weak interaction with H-ras was detected. The other five *RASSF*genes were also tested here, and showed no difference in their expression levels between MPNSTs and plexiform neurofibromas (Figure [3E](#F3){ref-type="fig"}). The second Ras signaling-associated gene identified here, *HMMR/RHAMM*, is an oncogene that regulates signaling through Ras and controls mitogen-activated protein kinase (ERK protein) expression \[[@B42]\]. However, *HMMR/RHAMM*has also recently been characterized as a centrosomal protein that interacts with dynein and maintains spindle pole stability \[[@B43]\]. Finally, *HMMR/RHAMM*has been identified as a major cell-cycle-regulated gene by cDNA microarray analysis \[[@B44]\].

Interesting, seven of the 28 genes showing significant differential expression between MPNSTs and plexiform neurofibromas are involved in the Hedgehog-Gli signaling pathway, namely *DHH*, *PATCH2*and five downstream target genes of Gli transcription factors (*SPP1/Osteopontin*, *FOXA2/HNF3B*, *FOXM1*, *OSF-2/Periostin*and *EPHA7*) \[[@B45]-[@B48]\]. The Hedgehog-Gli signaling pathway is important in regulating patterning, proliferation, survival and growth in both embryos and adults \[[@B49]\]. Inappropriate activation of the Hedgehog-Gli signaling pathway occurs in several tumor types, including brain and skin tumors \[[@B50]\]. *PTCH2*functions as a tumor suppressor gene, as its product normally inhibits SMOH (which functions as an oncogene), resulting in Gli inhibition. Mutations of human *PTCH1*and *PTCH2*have been detected in basal cell carcinomas and medulloblastomas, and result in Gli signaling activation \[[@B50]\]. Other genes associated with the Hedgehog-Gli signaling pathway were slightly (but not significantly) upregulated in MPNSTs, including *SMOH*, *HHIP*(a Hedgehog-interacting protein), three human *GLI*genes (*GLI2*, *GLI3*and *GLI4*; Figures [3F](#F3){ref-type="fig"}) and the major Gli-regulated genes *IGF2*, *PTHR1*and *H19*(Figures [3G](#F3){ref-type="fig"}) \[[@B47],[@B48],[@B51]\]. The eight Gli-regulated genes that we found altered in MPNSTs encode growth factors (*IGF2*, *SPP1/Osteopontin*, *OSF-2/Periostin*), growth factor receptors (*PTHR1*, *EPHA7*) and transcription factors (*FOXA2/HNF3B*, *FOXM1*), whereas *H19*yields an untranslated mRNA. Several of these genes are altered in various tumors \[[@B45],[@B52]-[@B54]\]. The positive correlation between *H19*and *IGF2*expression in our tumor series argues against abnormal *IGF2*imprinting as a source of IGF2 over-expression in MPNSTs. Indeed, a reduction or loss of H19 expression would be expected to result in increased IGF2 transcription, as expression of these two genes is functionally linked by their competition for a common enhancer \[[@B55]\].

We have previously found that *SHH*, *GLI1*, *IGF2*and *H19*are up-regulated in plexiform neurofibromas \[[@B23]\] (Figures [3F](#F3){ref-type="fig"} and [3G](#F3){ref-type="fig"}). Taken together, our results suggest that activation of the Hedgehog-Gli signaling pathway is not only an early event in the genesis of benign plexiform neurofibromas, but that it is also required for malignant transformation.

Conclusions
===========

In conclusion, this study points to the involvement of several altered molecular pathways, and especially the Hedgehog-Gli signaling pathway, in the tumorigenesis of NF1-associated MPNST. Further studies are necessary to elucidate the genetic (or epigenetic) mechanisms responsible for the altered gene expression. It will be of interest to study the genes identified here in sporadic MPNSTs and in other neurological tumors (medulloblastomas, oligodendrogliomas, astrocytomas, neuroblastomas and schwannomas).

Methods
=======

Patients and Samples
--------------------

Samples of 14 plexiform neurofibromas and 9 MPNSTs were obtained by surgical excision from patients with NF1 at Henri Mondor hospital (Creteil, France).

The plexiform neurofibromas (deep lesions involving a plexus of nerves) were large, had a nodular aspect, and severely deformed the affected tissues. They were all S100-positive by immunostaining.

The main clinical and histological characteristics of the 9 patients with MPNSTs are shown in Table [1](#T1){ref-type="table"}. The MPNSTs all arose from plexiform neurofibromas and showed very weak S100 immunostaining.

Ten dermal neurofibromas were used as \"normal\" controls, as they are not at risk of developing into malignant MPNSTs. Neurofibromas are heterogeneous benign tumors composed of Schwann cells, neurons, fibroblasts, mast cells and other cells, and have no \"normal\" tissue equivalent. The 489 gene expression levels in plexiform neurofibromas and MPNSTs were thus expressed relative to the expression levels in dermal neurofibromas. The dermal neurofibromas were obtained by laser excision from patients free of plexiform neurofibromas. They affected the dermis and subcutis, and were soft, slightly elevated, painless and smaller than 20 mm.

Immediately after surgery the tumor samples were flash-frozen in liquid nitrogen and stored at -80°C until RNA extraction.

Real-time RT-PCR
----------------

### Theoretical basis

Reactions are characterized by the point during cycling when amplification of the PCR product is first detected, rather than the amount of PCR product accumulated after a fixed number of cycles. The larger the starting quantity of the target molecule, the earlier a significant increase in fluorescence is observed. The parameter C~t~(threshold cycle) is defined as the fractional cycle number at which the fluorescence generated by cleavage of a TaqMan probe (or by SYBR green dye-amplicon complex formation) passes a fixed threshold above baseline. The increase in fluorescent signal associated with exponential growth of PCR products is detected by the laser detector of the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA), using PE Biosystems analysis software according to the manufacturer\'s manuals.

The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of two endogenous RNA control genes involved in two cellular metabolic pathways, namely *TBP*(Genbank accession NM_003194), which encodes the TATA box-binding protein (a component of the DNA-binding protein complex TFIID), and *RPLP0*(also known as 36B4; NM_001002), which encodes human acidic ribosomal phosphoprotein P0. Each sample was normalized on the basis of its *TBP*(or *RPLPO*) content.

Results, expressed as N-fold differences in target gene expression relative to the *TBP*(or *RPLPO*) gene, and termed \"N*target*\", were determined as ![](1476-4598-3-20-i1.gif), where the ΔCt value of the sample was determined by subtracting the average Ct value of the target gene from the average Ct value of the *TBP*(*or RPLP0*) gene \[[@B56],[@B57]\].

The N*target*values of the samples were subsequently normalized such that the mean of the dermal neurofibroma N*target*values was 1.

### Primers and controls

Primers for *TBP*, *RPLP0*and the 489 target genes (List in annex; supplementary information) were chosen with the assistance of the Oligo 5.0 computer program (National Biosciences, Plymouth, MN).

We conducted searches in dbEST, htgs and nr databases to confirm the total gene specificity of the nucleotide sequences chosen as primers, and the absence of single nucleotide polymorphisms. In particular, the primer pairs were selected to be unique relative to the sequences of closely related family member genes or of the corresponding retropseudogenes. To avoid amplification of contaminating genomic DNA, one of the two primers was placed at the junction between two exons, if possible. In general, amplicons were between 70 and 120 nucleotides long. Gel electrophoresis was used to verify the specificity of PCR amplicons.

For each primer pair, we performed no-template control (NTC) and no-reverse-transcriptase control (RT negative) assays, which produced negligible signals (usually \> 40 in Ct value), suggesting that primer-dimer formation and genomic DNA contamination effects were negligible.

### RNA extraction

Total RNA was extracted from frozen tumor samples by using the acid-phenol guanidinium method. The quality of the RNA samples was determined by electrophoresis through agarose gels and staining with ethidium bromide, the 18S and 28S RNA bands being visualized under ultraviolet light.

### cDNA Synthesis

Total RNA was reverse transcribed in a final volume of 20 μl containing 1X RT buffer (500 μM each dNTP, 3 mM MgCl2, 75 mM KCl, 50 mM Tris-HCl pH 8.3), 20 units of RNasin RNase inhibitor (Promega, Madison, WI), 10 mM DDT, 100 units of Superscript II RNase H-reverse transcriptase (Invitrogen, Cergy Pontoise, France), 3 μM random hexamers (Pharmacia, Uppsala, Sweden) and 100 ng of total RNA. The samples were incubated at 20°C for 10 min and 42°C for 30 min, and reverse transcriptase was inactivated by heating at 99°C for 5 min and cooling at 5°C for 5 min.

### PCR amplification

All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) and either the TaqMan^®^PCR Core REAGENTS Kit or the SYBR^®^Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems). Ten microliters of diluted sample cDNA (produced from 2 ng of total RNA) was added to 15 microliters of the PCR master-mix.

The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 min, and 50 cycles at 95°C for 15 s and 65°C for 1 min.

Statistical Analysis
--------------------

As the mRNA levels did not fit a Gaussian distribution, (a) the mRNA levels in each subgroup of samples were characterized by their median values and ranges, rather than their mean values and coefficients of variation, and (b) relationships between the molecular markers and clinical and histological parameters were tested using the non parametric Mann-Whitney *U*test \[[@B58]\]. Differences between two populations were judged significant at confidence levels greater than 95% (p \< 0.05).

To visualize the capacity of a given molecular marker to discriminate between two populations (in the absence of an arbitrary cutoff value), we summarized the data in a ROC (*receiver operating characteristic*) curve \[[@B59]\]. This curve plots the sensitivity (true positives) on the *Y*axis against 1-specificity (false positives) on the *X*axis, considering each value as a possible cutoff. The AUC (area under curve) was calculated as a single measure for the discriminatory capacity of each molecular marker. When a molecular marker had no discriminatory value, the ROC curve lies close to the diagonal and the AUC is close to 0.5. In contrast, when a molecular marker has strong discriminatory value, the ROC curve moves to the upper left-hand corner and the AUC is close to 1.0.
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